← Back

Mineralys Therapeutics, Inc. Common Stock

Mineralys Therapeutics, Inc. is a biopharmaceutical company that develops medicines targeting diseases driven by dysregulated aldosterone in the United States. Its lead candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Incorporated in 2019, it is headquartered in Radnor, Pennsylvania.

Country
Price · split & dividend adjusted
News & notes moving MLYS
MLYS▼4

Mineralys CMO David Rodman Sold $557,000 in Shares Under Pre-Set Trading Plan

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman sold 20,407 shares for approximately $557,000 on July 13 and 15, 2026, according to an SEC filing. The transaction was executed under a Rule 10b5-1 trading plan adopted on October 6, 2025, and involved the simultaneous exercise of 20,407 stock options at strike prices between $1.08 and $14.25 and an immediate open-market sale at a weighted average price of $27.28 per share. Following the sale, Rodman directly holds 51,384 shares, while retaining vested and unvested stock options. The sale occurred as Mineralys shares had returned 87% over the prior 12 months, with the company advancing its lead candidate lorundrostat ahead of a December 22 FDA decision date.
MLYS ▼
MLYS · Capital · Negative CMO sold $557k in shares under a 10b5-1 plan, which may signal insider sentiment despite the plan's pre-set nature.
Read original ↗
The Motley Fool·80dRead more →
MLYS▲

Mineralys Therapeutics Secures Up to $500 Million Loan and Gains Full Lorundrostat Rights

Mineralys Therapeutics has amended its agreement with Tanabe Pharma to obtain full worldwide rights to lorundrostat without future royalties, paying a $200 million upfront cash payment and up to $365 million in additional payments upon achieving certain commercial targets. The company also secured a loan of up to $500 million from funds managed by Pharmakon Advisors, provided in stages tied to FDA approval of lorundrostat and sales milestones. This financing will support growth and commercialization but increases debt obligations, potentially limiting financial flexibility. Goldman Sachs analyst Richard Law reiterated a Buy rating on the stock with a $42 target price on June 4.
MLYS ▲
MLYS · Capital · Positive Secured up to $500M loan and gained full worldwide rights to lorundrostat, with analyst reiterating Buy rating and $42 target.
Mitsubishi Tanabe Pharma Corporation · Capital · Negative Tanabe Pharma gave up future royalties on lorundrostat in exchange for upfront and milestone payments, losing potential long-term revenue.
Read original ↗
Insider Monkey·93dRead more →
Biotech & Genomic Medicine▲

Mineralys Therapeutics Presents Lorundrostat Heart Failure Biomarker Data at ENDO 2026

Mineralys Therapeutics presented new data on lorundrostat's impact on heart failure risk biomarkers at ENDO 2026. The post hoc analysis of Launch-HTN and Advance-HTN trial data showed lorundrostat influenced key renin-angiotensin-aldosterone system components, increasing renin and reducing angiotensinogen, and was associated with declines in heart failure risk biomarkers including NT-proBNP. The findings support further investigation of lorundrostat's role in heart failure pathways. Separately, the company priced a public offering of 5.66 million shares at $26.50 per share on June 3, expected to generate approximately $150 million in gross proceeds to help fund a portion of a $200 million upfront payment for repurchasing a royalty obligation under its license agreement with Tanabe Pharma Corporation, following the announcement of a $500 million committed debt facility managed by Pharmakon Advisors.
MLYS ▲
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Cardiovascular & Heart-Failure Therapeutics Technology
MLYS · Technology · Positive Positive biomarker data supports lorundrostat's potential in heart failure, a new indication.
MLYS · Capital · Negative Dilutive public offering of 5.66M shares at $26.50, raising $150M.
Mitsubishi Tanabe Pharma Corporation · Capital · Positive Mineralys repurchasing royalty obligation from Tanabe Pharma for $200M, providing cash to Tanabe.
Pharmakon Advisors, LP · Capital · Positive Pharmakon Advisors provided a $500M committed debt facility to Mineralys.
Read original ↗
Insider Monkey·94dRead more →
MLYS▼

Mineralys Therapeutics prices $150 million public offering of common stock

Mineralys Therapeutics has priced an underwritten public offering of approximately 5.66 million shares of its common stock at $26.50 per share, expecting to generate roughly $150 million in gross proceeds. The offering is scheduled to close on or about June 4, subject to customary closing conditions. The company intends to use the net proceeds to fund a significant portion of a $200 million upfront payment required to repurchase royalty obligations under its existing license agreement with Tanabe Pharma Corporation. This follows a separate announcement of a new $500 million committed debt facility with funds managed by Pharmakon Advisors, LP. BofA Securities, Goldman Sachs & Co. LLC, and Evercore ISI are serving as joint book-running managers for the transaction, which is being conducted under an existing shelf registration statement.
MLYS ▼
MLYS · Capital · Negative Company prices $150M stock offering, diluting existing shareholders to fund a royalty repurchase.
Mitsubishi Tanabe Pharma Corporation · Capital · Positive Mineralys will use offering proceeds to repurchase royalty obligations from Tanabe, providing a $200M upfront payment.
Pharmakon Advisors, LP · Capital · Positive Pharmakon Advisors provides a $500M committed debt facility to Mineralys, generating fee income and interest.
Read original ↗
Insider Monkey·109dRead more →
© 2026 MarketDXAsset